Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer

M. Timmermans*, M. A. van der Aa, R. Lalisang, P. O. Witteveen, K. K. Van de Vijver, R. F. Kruitwagen, G. S. Sonke

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)446-450
Number of pages5
JournalGynecologic Oncology
Volume150
Issue number3
DOIs
Publication statusPublished - Sep 2018

Keywords

  • Epithelial ovarian cancer
  • Primary debulking surgery
  • Neoadjuvant chemotherapy
  • Adjuvant chemotherapy
  • Timing
  • Overall survival
  • TIME-INTERVAL
  • NEOADJUVANT CHEMOTHERAPY
  • PROGNOSTIC IMPORTANCE
  • COMORBIDITY INDEX
  • CLINICAL-PRACTICE
  • INITIATION
  • CARCINOMA
  • IMPACT
  • METAANALYSIS
  • ONCOLOGY

Cite this